MG
CNCE

Michael Gelband’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Michael Gelband’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-16,198
Closed -$109K – 2298
2022
Q3 		$109K Buy
+16,198
New +$98.2K ﹤0.01% 1736
2021
Q3 		– Sell
-12,772
Closed -$54K – 2842
2021
Q2 		$54K Buy
+12,772
New +$54.1K ﹤0.01% 2214

Other funds holding CNCE

KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Michael Gelband's CNCE Position: Q4 2022 in Review

Michael Gelband sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2022, closing a stake of 16,198 shares — an estimated $109K sold.

Michael Gelband first reported a position in CNCE in Q2 2021 and held it in 2 quarters. The position peaked at $109K in Q3 2022. 85 funds tracked by Wall St. Rank hold CNCE as of Q4 2022.

  • Michael Gelband reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Michael Gelband sold 16,198 Concert Pharmaceuticals, Inc. shares in Q4 2022, an estimated $109K.
  • Michael Gelband first reported a position in Concert Pharmaceuticals, Inc. in Q2 2021 and held it in 2 quarters.
  • Michael Gelband's Concert Pharmaceuticals, Inc. position peaked at $109K in Q3 2022.
  • 85 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2022.

Based on ExodusPoint Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.